A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Latest Information Update: 08 Jun 2025
At a glance
- Drugs BGB A3055 (Primary) ; Tislelizumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeOne Medicines
Most Recent Events
- 21 May 2025 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2025 Planned number of patients changed from 318 to 263.
- 18 Mar 2025 Planned End Date changed from 1 Feb 2025 to 31 Mar 2027.